window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 24, 2026

  • News
  • About Us
Contact Us

IntelliSep

  • Clinical Trials,Technology and platforms

    Cytovale’s IntelliSep rapid sepsis test boosts ED discharges by 56% while maintaining patient safety

    A new multicenter study shows Cytovale’s rapid sepsis test IntelliSep [...]

    July 31, 2025
  • Clinical Development,Global health,Patient Centricity,Real world evidence,Research & Development,Technology and platforms

    Cytovale’s IntelliSep test drives 56% rise in safe ED discharges, easing pressure on hospital beds

    A new multicenter study has found that a rapid blood [...]

    July 28, 2025
  • Artificial Intelligence,Patient Centricity,Technology and platforms

    Rapid ED diagnostic linked to 39% drop in sepsis mortality, real-world study finds

    IntelliSep test from Cytovale shows potential to reshape emergency triage [...]

    July 1, 2025
  • Artificial Intelligence

    ICU level care not definitive indicator for sepsis, new study shows

    April 22, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma randomizes first patient in IMMUNOLIFE Phase 2 NSCLC microbiome study
    Categories: Uncategorised
  • Datwyler, LTS Device Technologies, and Stevanato Group collaborate on large-volume self-administration solutions
    Categories: Biologics & Biosimilars, Drug Delivery & Formulation, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
  • NeuroVice seizure oral injury device now available through BlinkRx
    Categories: Central Nervous System, Digital Health, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top